{
  "abstract": "Forging a novel path requires one to overcome resistance. This may explain the slow uptake of novel tools in medicine, where traditional measures continue to be used despite bodies of evidence informing their limitations. In the field of interstitial lung disease (ILD), this is perhaps best exemplified by the heavy reliance on forced vital capacity (FVC) as the key indicator of disease severity, clinical progression and response to therapy. FVC certainly plays an important role in the diagnosis, prognosis and monitoring of ILD and has been repeatedly shown as the preferred lung function outcome for clinical trials of therapeutics.1 However, in clinical practice and routine patient assessments, traditional pulmonary function test measures, including spirometry, have substantial limitations. They require patient collaboration and effort, are resource-intensive and cannot reliably differentiate distinct diagnostic subtypes of ILD from one another. When the differential diagnosis includes idiopathic pulmonary fibrosis (IPF) or fibrotic hypersensitivity pneumonitis (HP), a lung function tool to inform underlying biology, diagnosis and potentially response to treatment would be invaluable. Traditional spirometry may not be sufficiently sensitive to identify concomitant presence of small airway dysfunction and restrictive physiologic impairment that is characteristic of HP. Enter oscillometry.",
  "authors": [
    {
      "affiliations": [
        "McGill University, Montreal, Quebec, Canada"
      ],
      "name": "Deborah Assayag"
    },
    {
      "affiliations": [
        "Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada"
      ],
      "name": "Kerri A Johannson"
    }
  ],
  "title": "Respiratory oscillometry: the new kid on the lung function block",
  "uid": "5cab1f2b-00f6-5a04-8f51-f71bcbe8b391"
}